A Phase I Trial of the ATR inhibitor BAY 1895344 in combination with cisplatin and with cisplatin plus gemcitabine in advanced solid tumors with an emphasis on urothelial carcinoma
Sponsor: |
ETCTN |
Enrolling: |
Male and Female Patients |
IRB Number: |
AAAT6925 |
U.S. Govt. ID: |
NCT04491942 |
Contact: |
Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu |
This study is being done to answer the following question: What is the highest dose of BAY 1895344 that can be given safely in combination with cisplatin and gemcitabine in patients with advanced solid tumors, including urothelial carcinoma? We are doing this study because we want to find out if this approach is better or worse than the usual approach for your advanced solid tumor or urothelial carcinoma. The usual approach is defined as care most people get for advanced solid tumors or urothelial carcinoma. Cancers may include bladder cancer, breast cancer, lung cancer, gynecologic cancers, head and neck/oral cancers, and testicular cancer.
Investigator
Mark Stein, MD
Are you at least 18 years old? |
Yes |
No |
Do you have a solid tumor? |
Yes |
No |
Have you previously received chemotherapy? |
Yes |
No |
Are you able to make extra visits to the clinic for treatment and assessments? |
Yes |
No |